Symbols / GMAB Stock $26.47 +1.39% Genmab A/S

Healthcare • Biotechnology • Denmark • NMS
GMAB (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Dr. Jan G.J. van de Winkel Ph.D.
Exch · Country NMS · Denmark
Market Cap 16.25B
Enterprise Value 5.32B
Income 963.00M
Sales 3.72B
FCF (ttm) 1.07B
Book/sh 9.49
Cash/sh 27.83
Employees 2,973
Insider 10d —
IPO Jun 01, 2009
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E 17.19
Forward P/E 15.36
PEG 1.70
P/S 4.37
P/B 2.79
P/C —
EV/EBITDA 4.12
EV/Sales 1.43
Quick Ratio 2.01
Current Ratio 2.02
Debt/Eq 92.80
LT Debt/Eq —
EPS (ttm) 1.54
EPS next Y 1.72
EPS Growth -94.40%
Revenue Growth 3.00%
EPS Gr Q/Q -94.60%
Rev Gr Q/Q —
Earnings (next) 2026-05-07
Earnings (prior) 2026-02-17
ROA 8.10%
ROE 17.54%
ROIC —
Gross Margin 93.60%
Oper. Margin 22.97%
Profit Margin 25.89%
Shs Outstand 613.91M
Shs Float 60.89M
Insider Own 0.00%
Instit Own 12.09%
Short Float 1.31%
Short Ratio 5.05
Short Interest 7.93M
52W High 35.43
vs 52W High -25.28%
52W Low 18.89
vs 52W Low 40.17%
Beta 0.74
Impl. Vol. 3.13%
Rel Volume 0.08
Avg Volume 1.64M
Volume 125.90K
Target (mean) $37.68
Tgt Median $38.50
Tgt Low $30.50
Tgt High $48.00
# Analysts 11
Recom Strong_buy
Prev Close $26.11
Price $26.47
Change 1.39%
About

Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large B-cell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy. It is also developing Epcoritamab for R/R DLBCL and FL, first line DLBCL and FL, B-cell non-Hodgkin lymphoma, R/R chronic lymphocytic leukemia and Richter's syndrome, and aggressive mature B-cell neoplasms in pediatric patients; tisotumab vedotin for solid tumors; Acasunlimab for solid tumors and non-small cell lung cancer (NSCLC); Rinatabart Sesutecan for platinum resistant ovarian cancer and solid tumors; GEN1059, GEN1055, and GEN1057 for solid tumors; and GEN1286 for advanced solid tumors. In addition, the company offers DARZALEX/DARZALEX FASPRO for multiple myeloma (MM) and light-chain Amyloidosis; RYBREVANT for NSCLC; TECVAYLI and TALVEY for R/R MM; Kesimpta for Relapsing multiple sclerosis; and TEPEZZA for thyroid eye disease. Further, it is developing Amivantamab for recurrent/metastatic head and neck cancer, and advanced or metastatic colorectal cancer; Amlenetug for multiple system atrophy; Inclacumab for vaso-occulsive crises in sickle cell diseases; and Mim8 for hemophilia A. The company has a collaboration agreement with AbbVie Inc., Pfizer Inc., BioNTech SE, Johnson & Johnson, Medarex, Inc., Bristol Myers Squibb Corporation, Lundbeck A/S, Amgen Inc., Novo Nordisk A/S, and argenx. Genmab A/S was incorporated in 1998 and is headquartered in Copenhagen, Denmark.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$37.68
Mean price target
2. Current target
$26.47
Latest analyst target
3. DCF / Fair value
$31.32
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$26.47
Low
$30.50
High
$48.00
Mean
$37.68

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-04-30 main HC Wainwright & Co. Buy → Buy $38
2026-03-27 init Wolfe Research — → Outperform $32
2026-03-02 init Wells Fargo — → Overweight $40
2026-02-23 main Guggenheim Buy → Buy $40
2026-02-18 main HC Wainwright & Co. Buy → Buy $40
2026-01-28 reit HC Wainwright & Co. Buy → Buy $39
2026-01-20 main HC Wainwright & Co. Buy → Buy $39
2025-11-10 main HC Wainwright & Co. Buy → Buy $41
2025-11-07 reit Truist Securities Buy → Buy $48
2025-10-15 reit HC Wainwright & Co. Buy → Buy $40
2025-10-02 main HC Wainwright & Co. Buy → Buy $40
2025-09-24 up Guggenheim Neutral → Buy $43
2025-09-23 up Guggenheim Neutral → Buy $43
2025-08-15 main HC Wainwright & Co. Buy → Buy $36
2025-07-08 main Truist Securities Buy → Buy $46
2025-05-13 main HC Wainwright & Co. Buy → Buy $35
2025-04-09 reit HC Wainwright & Co. Buy → Buy $37
2025-03-11 main Truist Securities Buy → Buy $45
2025-03-11 up William Blair Market Perform → Outperform —
2025-02-13 up Leerink Partners Market Perform → Outperform $27
News
RSS: Latest GMAB news
Insider Transactions

No recent insider transactions.

Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
3,720.00
+19.19%
3,121.00
+30.59%
2,390.00
+14.48%
2,087.68
Operating Revenue
3,667.00
+23.18%
2,977.00
+31.38%
2,266.00
+15.03%
1,969.95
Cost Of Revenue
238.00
+66.43%
143.00
+333.33%
33.00
0.00
Reconciled Cost Of Revenue
238.00
+66.43%
143.00
+333.33%
33.00
0.00
Gross Profit
3,482.00
+16.92%
2,978.00
+26.35%
2,357.00
+12.90%
2,087.68
Operating Expense
2,232.00
+13.70%
1,963.00
+23.85%
1,585.00
+33.68%
1,185.68
Research And Development
1,606.00
+13.58%
1,414.00
+27.73%
1,107.00
+38.28%
800.53
Selling General And Administration
626.00
+14.03%
549.00
+14.85%
478.00
+24.11%
385.15
Total Expenses
2,470.00
+17.28%
2,106.00
+30.16%
1,618.00
+36.46%
1,185.68
Operating Income
1,250.00
+23.15%
1,015.00
+31.48%
772.00
-14.41%
902.00
Total Operating Income As Reported
1,065.00
+9.57%
972.00
+25.91%
772.00
-14.41%
902.00
EBITDA
1,336.00
-4.84%
1,404.00
+61.38%
870.00
-17.71%
1,057.30
Normalized EBITDA
1,459.00
+19.69%
1,219.00
+27.38%
957.00
-4.37%
1,000.73
Reconciled Depreciation
71.00
+18.33%
60.00
+39.53%
43.00
-17.47%
52.10
EBIT
1,265.00
-5.88%
1,344.00
+62.52%
827.00
-17.73%
1,005.20
Total Unusual Items
-123.00
-166.49%
185.00
+312.64%
-87.00
-253.81%
56.56
Total Unusual Items Excluding Goodwill
-123.00
-166.49%
185.00
+312.64%
-87.00
-253.81%
56.56
Special Income Charges
-185.00
-330.23%
-43.00
0.00
0.00
Restructuring And Mergern Acquisition
185.00
+330.23%
43.00
0.00
0.00
Net Income
963.00
-15.00%
1,133.00
+79.56%
631.00
-19.59%
784.70
Pretax Income
1,204.00
-9.20%
1,326.00
+62.30%
817.00
-18.27%
999.58
Net Non Operating Interest Income Expense
77.00
-38.89%
126.00
-4.55%
132.00
+221.80%
41.02
Interest Expense Non Operating
61.00
+238.89%
18.00
+80.00%
10.00
+78.15%
5.61
Net Interest Income
77.00
-38.89%
126.00
-4.55%
132.00
+221.80%
41.02
Interest Expense
61.00
+238.89%
18.00
+80.00%
10.00
+78.15%
5.61
Interest Income Non Operating
138.00
-4.17%
144.00
+1.41%
142.00
+204.51%
46.63
Interest Income
138.00
-4.17%
144.00
+1.41%
142.00
+204.51%
46.63
Other Income Expense
-123.00
-166.49%
185.00
+312.64%
-87.00
-253.81%
56.56
Gain On Sale Of Security
62.00
-72.81%
228.00
+362.07%
-87.00
-253.81%
56.56
Tax Provision
241.00
+24.87%
193.00
+3.76%
186.00
-13.44%
214.89
Tax Rate For Calcs
0.00
+36.99%
0.00
-35.87%
0.00
+5.90%
0.00
Tax Effect Of Unusual Items
-24.60
-191.08%
27.01
+236.37%
-19.81
-262.89%
12.16
Net Income Including Noncontrolling Interests
963.00
-15.00%
1,133.00
+79.56%
631.00
-19.59%
784.70
Net Income From Continuing Operation Net Minority Interest
963.00
-15.00%
1,133.00
+79.56%
631.00
-19.59%
784.70
Net Income From Continuing And Discontinued Operation
963.00
-15.00%
1,133.00
+79.56%
631.00
-19.59%
784.70
Net Income Continuous Operations
963.00
-15.00%
1,133.00
+79.56%
631.00
-19.59%
784.70
Normalized Income
1,061.40
+8.86%
975.01
+39.65%
698.19
-5.69%
740.29
Net Income Common Stockholders
963.00
-15.00%
1,133.00
+79.56%
631.00
-19.59%
784.70
Diluted EPS
—
1.69
+76.74%
0.96
-20.43%
1.20
Basic EPS
—
1.71
+76.32%
0.97
-20.44%
1.22
Basic Average Shares
—
641.87
-1.72%
653.10
-0.72%
657.83
Diluted Average Shares
—
646.33
-1.92%
658.98
-0.17%
660.10
Diluted NI Availto Com Stockholders
963.00
-15.00%
1,133.00
+79.56%
631.00
-19.59%
784.70
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
12,873.00
+100.70%
6,414.00
+22.59%
5,232.00
+20.69%
4,334.98
Current Assets
2,885.00
-26.03%
3,900.00
-20.60%
4,912.00
+20.94%
4,061.37
Cash Cash Equivalents And Short Term Investments
1,715.00
-41.94%
2,954.00
-29.18%
4,171.00
+29.81%
3,213.06
Cash And Cash Equivalents
1,715.00
+24.28%
1,380.00
-37.39%
2,204.00
+54.79%
1,423.88
Other Short Term Investments
0.00
-100.00%
1,574.00
-19.98%
1,967.00
+9.94%
1,789.17
Receivables
1,152.00
+22.95%
937.00
+27.83%
733.00
-13.59%
848.31
Accounts Receivable
1,112.00
+20.48%
923.00
+25.92%
733.00
-10.84%
822.12
Taxes Receivable
40.00
+185.71%
14.00
0.00
-100.00%
26.19
Inventory
18.00
+100.00%
9.00
+12.50%
8.00
0.00
Raw Materials
6.00
+500.00%
1.00
-50.00%
2.00
0.00
Work In Process
0.00
0.00
0.00
0.00
Finished Goods
13.00
+18.18%
11.00
+22.22%
9.00
0.00
Total Non Current Assets
9,988.00
+297.30%
2,514.00
+685.63%
320.00
+16.96%
273.61
Net PPE
280.00
+5.66%
265.00
+8.61%
244.00
+28.24%
190.27
Gross PPE
437.00
+14.40%
382.00
+11.05%
344.00
+31.54%
261.52
Accumulated Depreciation
-157.00
-34.19%
-117.00
-17.00%
-100.00
-40.36%
-71.24
Properties
0.00
0.00
0.00
0.00
Buildings And Improvements
—
—
686.00
+31.17%
523.00
Machinery Furniture Equipment
175.00
+25.90%
139.00
+2.96%
135.00
+44.52%
93.41
Construction In Progress
3.00
-78.57%
14.00
+133.33%
6.00
-82.11%
33.54
Other Properties
127.00
-0.78%
128.00
+25.49%
102.00
+35.50%
75.27
Leases
132.00
+30.69%
101.00
+0.00%
101.00
+70.32%
59.30
Goodwill And Other Intangible Assets
9,478.00
+355.02%
2,083.00
+13786.67%
15.00
-28.62%
21.01
Goodwill
355.00
+0.00%
355.00
0.00
—
Other Intangible Assets
9,123.00
+427.95%
1,728.00
+11420.00%
15.00
-89.73%
146.00
Investments And Advances
37.00
+15.63%
32.00
+60.00%
20.00
+4.48%
19.14
Other Investments
—
—
87.00
+815.86%
9.50
Non Current Accounts Receivable
22.00
+214.29%
7.00
-30.00%
10.00
+44.75%
6.91
Non Current Deferred Assets
171.00
+34.65%
127.00
+309.68%
31.00
-14.53%
36.27
Non Current Deferred Taxes Assets
171.00
+34.65%
127.00
+309.68%
31.00
-14.53%
36.27
Total Liabilities Net Minority Interest
7,026.00
+450.20%
1,277.00
+134.31%
545.00
+33.47%
408.32
Current Liabilities
1,427.00
+91.80%
744.00
+102.17%
368.00
+40.25%
262.38
Payables And Accrued Expenses
1,112.00
+52.75%
728.00
+108.00%
350.00
+41.71%
246.98
Payables
1,112.00
+52.75%
728.00
+108.00%
350.00
+41.71%
246.98
Accounts Payable
—
—
—
—
Other Payable
1,069.00
+118.61%
489.00
+42.98%
342.00
+38.47%
246.98
Pensionand Other Post Retirement Benefit Plans Current
—
—
—
—
Total Tax Payable
43.00
-82.01%
239.00
+2887.50%
8.00
0.00
Income Tax Payable
43.00
-82.01%
239.00
+2887.50%
8.00
0.00
Current Debt And Capital Lease Obligation
291.00
+2138.46%
13.00
+0.00%
13.00
+22.06%
10.65
Current Debt
273.00
—
—
—
Other Current Borrowings
273.00
—
—
—
Current Capital Lease Obligation
18.00
+38.46%
13.00
+0.00%
13.00
+22.06%
10.65
Current Deferred Liabilities
24.00
+700.00%
3.00
-40.00%
5.00
+5.27%
4.75
Current Deferred Revenue
24.00
+700.00%
3.00
-40.00%
5.00
+5.27%
4.75
Total Non Current Liabilities Net Minority Interest
5,599.00
+950.47%
533.00
+201.13%
177.00
+21.28%
145.94
Long Term Debt And Capital Lease Obligation
5,135.00
+3819.85%
131.00
+29.70%
101.00
+34.18%
75.27
Long Term Debt
5,001.00
—
—
—
Long Term Capital Lease Obligation
134.00
+2.29%
131.00
+29.70%
101.00
+34.18%
75.27
Long Term Provisions
—
—
—
—
Tradeand Other Payables Non Current
5.00
+0.00%
5.00
+0.00%
5.00
+215.81%
1.58
Non Current Deferred Liabilities
459.00
+15.62%
397.00
+459.15%
71.00
+2.77%
69.09
Non Current Deferred Revenue
95.00
+41.79%
67.00
-5.63%
71.00
+2.77%
69.09
Non Current Deferred Taxes Liabilities
364.00
+10.30%
330.00
0.00
—
Stockholders Equity
5,847.00
+13.82%
5,137.00
+9.60%
4,687.00
+19.36%
3,926.65
Common Stock Equity
5,847.00
+13.82%
5,137.00
+9.60%
4,687.00
+19.36%
3,926.65
Capital Stock
10.00
+0.00%
10.00
+0.00%
10.00
+5.27%
9.50
Common Stock
10.00
+0.00%
10.00
+0.00%
10.00
+5.27%
9.50
Share Issued
64.24
-2.94%
66.19
+0.17%
66.07
+0.17%
65.96
Ordinary Shares Number
61.60
-3.05%
63.54
-2.74%
65.33
-0.06%
65.37
Treasury Shares Number
2.64
-0.30%
2.65
+255.70%
0.74
+26.14%
0.59
Additional Paid In Capital
1,920.00
-2.09%
1,961.00
+0.98%
1,942.00
+9.62%
1,771.61
Retained Earnings
4,098.00
+20.81%
3,392.00
+23.93%
2,737.00
+28.41%
2,131.44
Gains Losses Not Affecting Retained Earnings
-181.00
+19.91%
-226.00
-11200.00%
-2.00
-114.18%
14.10
Other Equity Adjustments
-181.00
+19.91%
-226.00
-11200.00%
-2.00
-102.04%
98.00
Total Equity Gross Minority Interest
5,847.00
+13.82%
5,137.00
+9.60%
4,687.00
+19.36%
3,926.65
Total Capitalization
10,848.00
+111.17%
5,137.00
+9.60%
4,687.00
+19.36%
3,926.65
Working Capital
1,458.00
-53.80%
3,156.00
-30.55%
4,544.00
+19.61%
3,798.99
Invested Capital
11,121.00
+116.49%
5,137.00
+9.60%
4,687.00
+19.36%
3,926.65
Total Debt
5,426.00
+3668.06%
144.00
+26.32%
114.00
+32.67%
85.93
Net Debt
3,559.00
—
—
—
Capital Lease Obligations
152.00
+5.56%
144.00
+26.32%
114.00
+32.67%
85.93
Net Tangible Assets
-3,631.00
-218.89%
3,054.00
-34.63%
4,672.00
+19.62%
3,905.64
Tangible Book Value
-3,631.00
-218.89%
3,054.00
-34.63%
4,672.00
+19.62%
3,905.64
Available For Sale Securities
—
—
—
67.00
Financial Assets Designatedas Fair Value Through Profitor Loss Total
37.00
+15.63%
32.00
+60.00%
20.00
—
Foreign Currency Translation Adjustments
—
68.36
+667.41%
8.91
-36.84%
14.10
Inventories Adjustments Allowances
-1.00
+66.67%
-3.00
+0.00%
-3.00
0.00
Investmentin Financial Assets
37.00
+15.63%
32.00
+60.00%
20.00
+107.40%
9.64
Trading Securities
—
—
47.00
+387.39%
9.64
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
1,186.00
+5.33%
1,126.00
+5.14%
1,071.00
+90.21%
563.05
Cash Flow From Continuing Operating Activities
1,186.00
+5.33%
1,126.00
+5.14%
1,071.00
+90.21%
563.05
Net Income From Continuing Operations
1,204.00
-9.20%
1,326.00
+62.30%
817.00
-18.27%
999.58
Depreciation Amortization Depletion
71.00
+18.33%
60.00
+39.53%
43.00
-17.47%
52.10
Depreciation
55.00
+12.24%
49.00
+22.50%
40.00
+25.19%
31.95
Amortization Cash Flow
16.00
+45.45%
11.00
+266.67%
3.00
-85.11%
20.15
Depreciation And Amortization
71.00
+18.33%
60.00
+39.53%
43.00
-17.47%
52.10
Amortization Of Intangibles
16.00
+45.45%
11.00
+266.67%
3.00
-85.11%
20.15
Other Non Cash Items
-77.00
+38.89%
-126.00
+4.55%
-132.00
-221.80%
-41.02
Stock Based Compensation
128.00
+21.90%
105.00
+23.53%
85.00
+34.53%
63.18
Asset Impairment Charge
32.00
+88.24%
17.00
0.00
0.00
Operating Gains Losses
-62.00
+72.81%
-228.00
-362.07%
87.00
+253.81%
-56.56
Gain Loss On Investment Securities
-65.00
+52.21%
-136.00
-747.62%
21.00
-77.83%
94.70
Net Foreign Currency Exchange Gain Loss
3.00
+103.26%
-92.00
-239.39%
66.00
+143.63%
-151.27
Change In Working Capital
225.00
+306.42%
-109.00
-155.05%
198.00
+174.77%
-264.83
Change In Receivables
-166.00
+27.83%
-230.00
-298.28%
116.00
+137.96%
-305.56
Change In Inventory
-9.00
-800.00%
-1.00
+87.50%
-8.00
0.00
Change In Payables And Accrued Expense
400.00
+227.87%
122.00
+35.56%
90.00
+120.96%
40.73
Change In Payable
400.00
+227.87%
122.00
+35.56%
90.00
+120.96%
40.73
Investing Cash Flow
-5,643.00
-289.98%
-1,447.00
-682.16%
-185.00
+53.45%
-397.39
Cash Flow From Continuing Investing Activities
-5,643.00
-289.98%
-1,447.00
-682.16%
-185.00
+53.45%
-397.39
Net PPE Purchase And Sale
-37.00
-37.04%
-27.00
+49.06%
-53.00
-16.16%
-45.63
Purchase Of PPE
-37.00
-37.04%
-27.00
+49.06%
-53.00
-16.16%
-45.63
Capital Expenditure
-55.00
-25.00%
-44.00
+18.52%
-54.00
-18.36%
-45.63
Net Investment Purchase And Sale
1,627.00
+328.16%
380.00
+390.08%
-131.00
+62.76%
-351.76
Purchase Of Investment
-995.00
+20.78%
-1,256.00
+20.61%
-1,582.00
-13.34%
-1,395.82
Sale Of Investment
2,622.00
+60.27%
1,636.00
+12.75%
1,451.00
+38.98%
1,044.06
Net Business Purchase And Sale
0.00
+100.00%
-1,783.00
0.00
0.00
Purchase Of Business
0.00
+100.00%
-1,783.00
0.00
0.00
Net Intangibles Purchase And Sale
-18.00
-5.88%
-17.00
-1600.00%
-1.00
0.00
Purchase Of Intangibles
-18.00
-5.88%
-17.00
-1600.00%
-1.00
0.00
Net Other Investing Changes
-7,215.00
—
—
—
Financing Cash Flow
4,789.00
+946.11%
-566.00
-535.96%
-89.00
+21.63%
-113.56
Cash Flow From Continuing Financing Activities
4,789.00
+946.11%
-566.00
-535.96%
-89.00
+21.63%
-113.56
Net Issuance Payments Of Debt
-13.00
-44.44%
-9.00
+35.71%
-14.00
-33.25%
-10.51
Repayment Of Debt
-13.00
-44.44%
-9.00
+35.71%
-14.00
-33.25%
-10.51
Long Term Debt Payments
-13.00
-44.44%
-9.00
+35.71%
-14.00
-33.25%
-10.51
Net Long Term Debt Issuance
-13.00
-44.44%
-9.00
+35.71%
-14.00
-33.25%
-10.51
Net Common Stock Issuance
5,070.00
+1005.36%
-560.00
-591.36%
-81.00
+38.02%
-130.69
Common Stock Payments
-430.00
+23.21%
-560.00
-591.36%
-81.00
+38.02%
-130.69
Repurchase Of Capital Stock
-430.00
+23.21%
-560.00
-591.36%
-81.00
+38.02%
-130.69
Proceeds From Stock Option Exercised
23.00
+21.05%
19.00
-9.52%
21.00
-47.89%
40.30
Net Other Financing Charges
-291.00
-1718.75%
-16.00
-6.67%
-15.00
-18.43%
-12.67
Changes In Cash
332.00
+137.43%
-887.00
-211.29%
797.00
+1429.69%
52.10
Effect Of Exchange Rate Changes
3.00
-95.24%
63.00
+625.00%
-12.00
-114.53%
82.61
Beginning Cash Position
1,380.00
-37.39%
2,204.00
+55.32%
1,419.00
+10.07%
1,289.17
End Cash Position
1,715.00
+24.28%
1,380.00
-37.39%
2,204.00
+54.79%
1,423.88
Free Cash Flow
1,131.00
+4.53%
1,082.00
+6.39%
1,017.00
+96.55%
517.42
Common Stock Issuance
5,500.00
0.00
0.00
—
Interest Paid CFO
-10.00
-100.00%
-5.00
-66.67%
-3.00
-30.27%
-2.30
Interest Received CFO
135.00
-0.74%
136.00
+3.82%
131.00
+221.62%
40.73
Issuance Of Capital Stock
5,500.00
0.00
0.00
—
Taxes Refund Paid
-460.00
-820.00%
-50.00
+67.74%
-155.00
+31.97%
-227.84
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category